# Effect of Antimuscarinic Treatment on Premature Ejaculation Severity in Men With Overactive Bladder: a Prospective Comparison With Mirabegron

> **NCT07736560** · — · COMPLETED · sponsor: **Başakşehir Çam & Sakura City Hospital** · enrollment: 40 (actual)

## Conditions studied

- Overactive Bladder (OAB)
- Premature (Early) Ejaculation
- Ejaculation Abnormal

## Interventions

- **DRUG:** Tolterodine
- **DRUG:** Mirabegron (beta3-adrenoceptor agonist)

## Key facts

- **NCT ID:** NCT07736560
- **Lead sponsor:** Başakşehir Çam & Sakura City Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2026-01-15
- **Primary completion:** 2026-06-20
- **Final completion:** 2026-06-30
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2026-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07736560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07736560, "Effect of Antimuscarinic Treatment on Premature Ejaculation Severity in Men With Overactive Bladder: a Prospective Comparison With Mirabegron". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07736560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*